Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.79), $0.09 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $144.1 million versus the consensus estimate of $146.14 million.

GUIDANCE:

Blueprint Medicines sees FY2025 revenue of $680-710 million, versus the consensus of $726.2 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.